# A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)

> **NCT02229422** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University of California, San Diego** · enrollment: 40 (actual)

## Conditions studied

- CLL

## Interventions

- **DRUG:** GA101/HDMP

## Key facts

- **NCT ID:** NCT02229422
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2025-10-30
- **Final completion:** 2025-12-25
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229422, "A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02229422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*